Stroke Risk Reduction in Atrial Fibrillation Through Pharmacist Prescribing: A Randomized Clinical Trial
Key Findings:
Pharmacist-led oral anticoagulation therapy (OAC) prescription significantly increased the delivery of stroke risk reduction therapy in individuals with atrial fibrillation (AF).
Guideline-concordant OAC use at 3 months occurred in 92.3% of patients in the early intervention group vs 56.1% in the control group, with an absolute increase of 34% and number needed to treat of 3.
Practical Solutions:
Pharmacist-led OAC prescription presents a high-yield opportunity to effectively close gaps in the delivery of stroke risk reduction therapy for AF.
Using AI-driven platforms like DocSym can consolidate standards, protocols, and research into a single, easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
Streamlining operations with mobile apps can support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
Value:
Scalability and sustainability of pharmacist OAC prescription will require larger trials demonstrating effectiveness and safety, offering potential for enhanced workflows and improved patient outcomes.
AI-driven solutions can help clinics reduce paper routines and enhance their workflows, ultimately improving patient care and operational efficiency.
Learn more about how AI can enhance clinic workflows and patient outcomes at aidevmd.com.
